Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Broxaldine SCHEMBL29888411 | 1.00 | ALOX5 (0.41) | ALOX5MAPTLMNAGAAHTT | |
| SCHEMBL18106114 | 0.90 | GAA (0.38) | ALOX5MAPTGAAHTTKDM4E | |
| SCHEMBL18106122 | 0.82 | KDM4E (0.42) | MAPTGAAHTTKDM4EPKM | |
| SCHEMBL9951316 | 0.81 | KDM4E (0.49) | MAPTLMNAGAAHTTKDM4E | |
| SCHEMBL18106119 | 0.81 | MAPT (0.45) | MAPTLMNAGAAHTTKDM4E | |
| SCHEMBL16862273 | 0.77 | NQO2 (0.59) | MAPTLMNAHTTKDM4EMETAP2 | |
| SCHEMBL7690476 | 0.74 | NQO2 (0.50) | MAPTLMNAGAAHTTKDM4E | |
| SCHEMBL9956727 | 0.74 | PARP1 (0.37) | MAPTLMNAGAAHTTKDM4E | |
| SCHEMBL18294117 | 0.73 | NQO2 (0.57) | MAPTLMNAKMT2AMEN1RAB9A | |
| SCHEMBL16867454 | 0.73 | NQO2 (0.57) | MAPTGAAPKMKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3803402-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2023-04-26 | — | — | EP | claimed |
| EP-3829640-A1 | METHODS FOR INHIBITING MICROBE GROWTH | McMaster University (CA) | 2021-06-09 | — | — | EP | claimed |
| US-20200325543-A1 | DIAGNOSTIC METHOD | TOLREMO THERAPEUTICS AG (CH) | 2020-10-15 | — | — | US | claimed |
| EP-3714069-A1 | DIAGNOSTIC METHOD | Tolremo Therapeutics AG (CH) | 2020-09-30 | — | — | EP | claimed |
| WO-2020024060-A1 | METHODS FOR INHIBITING MICROBE GROWTH | MCMASTER UNIVERSITY (CA) | 2020-02-06 | — | — | WO | claimed |
| US-10184933-B2 | Compositions, systems and methods for gene expression noise drug screening and uses thereof | The J. David Gladstone Industries (US) | 2019-01-22 | — | — | US | claimed |
| US-20160245796-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-08-25 | — | — | US | claimed |
| EP-3052662-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | The J. David Gladstone Institutes (US) | 2016-08-10 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2015051035-A1 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | THE J. DAVID GLADSTONE INSTITUTES (US) | 2015-04-09 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | disclosed |
| EP-3803402-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | ALOX5 647/4885MAPT 3135/4885LMNA 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.